Suggested Dosing
Cardiac Glycosides
Insufficient reliable evidence available for effectiveness
600 mg/day PO average amount
Tincture: 6 g/day divided TID PO
Liquid extract: 600 mg/day divided TID PO
Dried extract: 150 mg/day PO
Suggested Uses
Circulatory disorders, heart palpitations, arrhythmia, CHF, cardiac edema, cardiac asthma, kidney and bladder stones, UTI
Efficacy
Contains cardiac glycosides similar to those in digitalis
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (1)
- digoxin
digoxin, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated.
Monitor Closely (13)
- bendroflumethiazide
bendroflumethiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- bumetanide
bumetanide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- chlorothiazide
chlorothiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- chlorthalidone
chlorthalidone increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- cyclopenthiazide
cyclopenthiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- ethacrynic acid
ethacrynic acid increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- furosemide
furosemide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- hydrochlorothiazide
hydrochlorothiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- indapamide
indapamide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- methyclothiazide
methyclothiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- metolazone
metolazone increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- senna
senna increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
- torsemide
torsemide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.
Minor (23)
- acebutolol
acebutolol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- adenosine
adenosine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- amiodarone
amiodarone, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- calcium acetate
calcium acetate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.
- calcium carbonate
calcium carbonate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.
- calcium chloride
calcium chloride increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.
- calcium citrate
calcium citrate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.
- calcium gluconate
calcium gluconate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.
- diltiazem
diltiazem, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- disopyramide
disopyramide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- encainide
encainide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- esmolol
esmolol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- flecainide
flecainide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- ibutilide
ibutilide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- lidocaine
lidocaine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- mexiletine
mexiletine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- phenytoin
phenytoin, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- procainamide
procainamide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- propafenone
propafenone, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- propranolol
propranolol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- quinidine
quinidine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- sotalol
sotalol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- verapamil
verapamil, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
Warnings
Contraindications
High BP, kidney/liver disease, potassium deficiency
Pregnancy
Cautions
Use only under qualified supervision: potentially fatal if overdosed
Taking more than recommended dose may cause nausea, vomiting, headache, stupor, disorders of color perception, and irregular heartbeat
Pregnancy & Lactation
Pregnancy Category: avoid
Lactation: N/A
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Cardiac glycosides increase force and power of heartbeat without increasing amount of oxygen required by cardiac muscle